Research Article

The Expression of Soluble and Active Recombinant
Haemophilus influenzae IgA1 Protease in E. coli

Shinong Long, Elaine Phan, and Michel C. Vellard

Department of Cellular and Molecular Biology, BioMarin Pharmaceutical Inc., 105 Digital Drive, Novato, CA 94949, USA

Correspondence should be addressed to Shinong Long, slong@bmrn.com

Received 9 August 2010; Accepted 4 October 2010

Academic Editor: Lori Snyder

Copyright © 2010 Shinong Long et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Immunoglobulin A1 (IgA1) proteases from Haemophilus influenzae are extracellular proteases that specifically cleave the hinge region of human IgA1, the predominant class of immunoglobulin present on mucosal membranes. The IgA1 proteases may have the potential to cleave IgA1 complexes in the kidney and be a therapeutic agent for IgA1 nephropathy (IgAN), a disease characterized by deposition of the IgA1 antibody in the glomerulus. We have screened for the expression of recombinant H. influenzae IgA1 protease by combining various expression plasmids, IgA1 protease constructs, and E. coli strains under multiple conditions. Using the method we have developed, approximately 20–40 mg/L of soluble and active H. influenzae IgA1 protease can be produced from E. coli strain C41(DE3), a significant increase in yield compared to the yield upon expression in H. influenzae or other related bacteria.

1. Introduction

Immunoglobulin A1 (IgA1) proteases from bacteria, such as Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus sanguis, Streptococcus oralis, Streptococcus mitis, Clostridium ramosum, Prevotella melanogenica, and other bacterial strains are a group of proteases that specifically cleave the IgA1 hinge region of human IgA1 and some great apes. IgA1 proteases neither cleave human IgA2, IgG, and IgM nor do they cleave IgA from mice, rat, or even monkey [1–3]. The C. ramosum IgA protease, in addition, cleaves human IgA2m(1) allotype [4]. In addition to the IgA1 hinge length and composition [5–7], structures in the Fc region [8] and different sites in the CH3 domain [9] of IgA1 are required for cleavage.

IgA1 proteases are comprised of at least three families having different structural forms including serine-, metallo-, and cysteine-type proteases. The serine type IgA1 proteases are expressed as a precursor protein comprising a signal peptide, an IgA1 protease domain, and a C-terminal α protein and β-core domain. The C-terminal β-core domain targets the protein to the cell membrane and facilitates secretion of a α protein-protease domain polypeptide. The β domain and α protein are cleaved from the precursor polypeptide leaving the protease domain as the mature protease. The metallo-type IgA1 proteases comprise a signal sequence and propeptide which aids in anchoring the peptide to the cell membrane and contains several sites for metal ion (e.g., zinc) binding in the protease domain. The structure for the cysteine-type IgA1 protease has yet to be determined. The IgA1 proteases of H. influenzae and Neisseria species are of the serine type. For serine type IgA1 proteases, cleavage between proline and serine is designated as type 1 whereas cleavage between proline and threonine is designated as type 2. Those IgA1 proteases produced by streptococcal species are of the metallo type; the C. ramosum IgA protease has a unique sequence and is a different type of metalloproteinase.

IgA1 nephropathy (IgAN), a disease characterized by deposition of the IgA1 antibody in the glomerulus, can lead to kidney dysfunction and, in certain cases, kidney failure [16]. Exogenous proteolytic enzymes have been tested as therapy to treat IgA1 deposition in animal models in an attempt to remove IgA1 deposits in the kidneys. The administered proteases, chymopapain and subtilisin, act by proteolytic cleavage of IgA1 deposits in the kidney but are not specific for IgA1 molecules and digest a variety of other proteases.
proteins [17, 18]. The IgA1-specific IgA1 protease from *H. influenzae* has been used to treat IgAN in animal models. The *H. influenzae* IgA1 protease reduced the deposition of glomerular IgA immune complexes in a passive mouse model [19]. IgA1 protease may have potential as a therapeutic agent for IgAN.

Production of IgA1 protease in amounts sufficient for therapeutic use has not been achieved due to the low natural production of the protein in naturally producing cells such as *H. influenzae*, *N. gonorrhoeae*, and *N. meningitidis*. Moreover, *H. influenzae*, *N. gonorrhoeae*, and *N. meningitidis* are pathogenic bacterial species, and *H. influenzae* requires hemin for growth which makes it impractical for production of IgA1 proteases at a large scale. The soluble and active IgA1 proteases from *S. pneumoniae*, *S. suis*, and *C. ramosum* have been expressed in *E. coli* at a low yield [4, 20, 21]. We report here a method of only expressing the protease domain (without α protein and β-core domain) of *H. influenzae* IgA1 protease in *E. coli*, wherein the yield and total recovery of soluble and active recombinant IgA1 protease are significantly increased compared to previous methods.

## 2. Materials and Methods

### 2.1. Cloning of IgA1 Protease into Expression Vectors. IgA1 protease-encoding DNA fragments were amplified from pFG26 plasmid (from Jiazhou Qiu and Andrew G. Plaut of Tufts Medical Center, containing full-length wild-type *H. influenzae* IgA protease gene, GenBank: X59800) by PCR using different pair of primers (Figure 1 and Table 1). Amplified PCR fragments were digested with Nde I and BamHI and cloned into pET21a (Novagen) and pColdIV (Takara) vectors (Table 1).

### 2.2. Expression of IgA1 Protease in *E. coli*. Bacterial strains [BL21(DE3), BL21(DE3)pLysS, ArcticExpress(DE3) (Stratagene); BL21(DE3)pGro7 (Takara); C41(DE3), C43(DE3), C41(DE3)pLysS, C43(DE3)pLysS (Lucigen); Origami B(DE3), Origami B(DE3)pLysS, Tuner(DE3) (Novagen); KRX (Promega)] containing plasmids (pET-S-IGAN, pET-IGAN, pCold-IGAN, or pCold-S-IGAN) were cultured in 4 ml LB medium containing 100 μg/ml of carbenicillin at 37°C with shaking. When OD600 of bacterial culture reached 0.6, IPTG was added to a final concentration of 0.2–1 mM and incubated at 12°C–30°C for 3–24 hours with shaking. Bacterial cell pellets were collected by centrifugation at 5000 rpm and 4°C for 10 minutes and lysed with 1 ml B-PER II Bacterial Extraction Reagent (Thermo) with Benzonase Nuclease (Novagen). The total cell lysates were centrifuged at 14000 rpm and 4°C for 15 minutes. The supernatants were assayed for protein concentration with BCA protein Assay Reagent (Thermo) and adjusted to have the same total protein concentration with B-PER II.

### 2.3. Immunodetection of IgA1 Protease Expression. Total cell lysates or soluble supernatants were separated by SDS-PAGE (reduced gel) and electrotransferred to a nitrocellulose membrane with iBlot (Invitrogen). The membrane was blocked with 5% non-fat milk powder in TBS-T buffer containing 0.05% Tween 20 and incubated with rabbit anti-his polyclonal Ab (Abcam, 0.4 μg/ml) at RT for 2 hours. The membrane was washed three times with TBS buffer and incubated with AP-conjugated antirabbit IgG (Promega, 0.2 μg/ml) at RT for 1 hour. The membrane was washed three times with TBS buffer, and the expressed proteins were visualized by adding 10 ml Western Blue Stabilized Substrate (Promega).

### 2.4. IgA1 Protease Activity Assay. The activity of IgA1 proteases from cell lysates and supernatants was determined by Western blotting. The positive control (purified IgA1 protease from *H. influenzae*, supplied by Jiazhou Qiu and Andrew G. Plaut of Tufts Medical Center) and negative controls as well as 10 μl of cell lysates or soluble supernatants were added to 10 μl of human IgA1 (1 mg/ml, supplied by CalBiochem and Paul Fitzpatrick of BioMarin), mixed well and incubated at 37°C overnight. The samples were separated by SDS-PAGE (reduced gel) and electrotransferred

Figure 1: IgA protease expression constructs. Only the IgA protease domains with or without the signal peptide were cloned into pET21a and pCold IV expression vectors. S: signal peptide for targeting to the periplasm; a, b, c: the three IgA1 protease self-cleavage sites delineating the different domains.
Table 1: IgA1 protease expression constructs.

| Construct       | Vector   | Primer                                      | Tag                | Expression location |
|-----------------|----------|---------------------------------------------|--------------------|--------------------|
| pET-S-IGAN      | pET21a   | IgA-Ndel-5′: gcctatgtctaatataaatcaactc      | C-terminal His tag | E. coli periplasm  |
|                 |          | IgA-6his-BamHI-3′: caggtattcctagtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtg...
Figure 2: pET-S-IGAN and pET-IGAN IgA1 proteases were expressed in E. coli as inclusion bodies. The expressions of pET-S-IGAN and pET-IGAN were induced in BL21(DE3) cells with 1 mM IPTG at 30°C for 3 hours. The total cell lysates and soluble supernatants were analyzed with SDS-PAGE (reduced condition) and Western blot.

3. Results

3.1. Expression of IgA1 Proteases in E. coli. The serine-type IgA1 protease is initially translated as a precursor composed of four functional domains: (i) an amino-terminal signal peptide to target it through the inner membrane to the periplasm; (ii) the mature protease domain; (iii) the \( \alpha \)-protein domain, and (iv) the \( \beta \)-core domain for transport across the outer membrane. The \( \beta \)-core domain integrates into the outer membrane and forms a pore structure that the mature protease domain and the \( \alpha \)-protein domain are translocated through the \( \beta \)-core domain channel into the extracellular space. The mature IgA1 protease is released by self-cleavage at three cleavage sites: a, b, and c (Figure 1) [10, 22, 23]. Here, only the mature protease domain with or without signal peptide was cloned and expressed in E. coli. The C-terminal His-tagged IgA1 protease domain with the signal peptide (S) was amplified by PCR and cloned into pET21a expression vector (using T7 promoter) and pCold IV expression vector (using cold shock promoter, expression occurs at low temperature) (pET-S-IGAN and pCold-S-IGAN) for periplasmic expression. The C-terminal His-tagged IgA1 protease domain only was also amplified by PCR and cloned into pET21a and pCold IV vectors (pET-IGAN and pCold-IGAN) for cytoplasmic expression (Figure 1 and Table 1). pET-S-IGAN and pET-IGAN were first expressed in BL21(DE3) cells induced with 1 mM IPTG at 30°C for 3 hours. The majority of IgA1 proteases were detected in total cell lysates which are shown as a band with molecular weight around 100 kDa (Figure 2, Lanes 3, 5, 7, and 9) rather than the cell supernatants (Figure 2, Lanes 4, 6, 8, and 10) indicating that both constructs resulted in expression of IgA1 proteases as inclusion bodies.

When the expression of pET-S-IGAN and pET-IGAN was induced at low temperature (12°C) and a low concentration of IPTG (0.4 mM) in different cell strains (BL21(DE3), C41(DE3), C43(DE3), BL21(DE3)pGro7, and Origami B(DE3), Origami B(DE3)pLysS), small fractions of expressed IgA proteases were soluble, as evidenced by the detection of IgA1 protease in the cell supernatant (data not shown). When the expression of pCold-S-IGAN and pCold-IGAN was induced at low temperature (12°C) and low concentration of IPTG (0.4 mM) in different cell strains (BL21(DE3), C41(DE3), C43(DE3), BL21(DE3)pGro7, and Origami B(DE3), Origami B(DE3)pLysS), small fractions of expressed IgA proteases were soluble, as evidenced by the detection of IgA1 protease in the cell supernatant (Figure 3).

The expressed IgA1 proteases from the four constructs described above expressed in different E. coli cells were tested for IgA1 cleavage activity by Western blotting. All IgA1 proteases expressed in the above assays exhibited IgA1...
cleavage activity (Figure 4). The high molecular weight bands in Figure 4 lanes 7 and 9 may indicate cross-reactivity of the anti-IgA detecting antibody with the IgA1 protease itself.

3.2. Screening Soluble IgA1 Protease Expression Levels with ELISA. ELISA was used to quantify expression levels of IgA1 protease expressed by all four IgA protease constructs described above (pET-S-IGAN, pET-IGAN, pCold-S-IGAN, and pCold-IGAN), whose expression was induced at low temperature (12°C) and low concentration of IPTG (0.4 mM) in various cell strains. The pET-IGAN construct resulted in the production of higher levels of soluble IgA1 protease in several cell strains (Table 2, in bold italic font). We then tested the expression of pET-IGAN induced at various temperatures and concentrations of IPTG in and various cell strains. Overall, greater amounts of soluble IgA1 protease were produced at 20°C with 0.4 mM IPTG in most cell strains. The C41 (DE3) strain produced the highest titer of protease under the same conditions compared with other E. coli strains used for recombinant expression (Table 2, in bold font). The soluble IgA1 protease was purified by a nickel column and further purified by an anion-exchange column and a size-exclusion column to more than 95% pure (Figure 6, Lane 2: C41 IgA1 protease). The final yield of purified IgA1 protease was 20–40 mg/L from approximately 100 mg/L of total soluble expressed IgA1 protease. We have developed a novel IgA1 protease activity assay using an Experion automated electrophoresis system. The proteolytic activity of the IgA1 protease was measured as the decrease in IgA1 concentration per minute (ng/μL/min/ng of IgA1 protease).

Using the method we developed, the average activities of purified IgA1 protease from E. coli C41 (DE3) and IgA1 protease from H. influenzae (from Jiazhou Qiu and Andrew G. Plaut of Tufts Medical Center) were approximately 46 and 27 ng/μL/min per ng of IgA1 protease, respectively. The IgA1 protease produced from H. influenzae showed lower activity in this experiment probably due to impurity or degradation of the H. influenzae IgA1 protease sample (Figure 6, the extra low molecular weight band in the first line: HI IgA1 protease).

3.3. Characterization of IgA1 Proteases. The soluble IgA1 protease was produced from E. coli strain C41 (DE3) containing pET-IGAN plasmid with 0.4 mM IPTG induction at 20°C. The soluble IgA1 protease was purified by a nickel column and further purified by an anion-exchange column and a size-exclusion column to more than 95% pure (Figure 6, Lane 2: C41 IgA1 protease). The final yield of purified IgA1 protease was 20–40 mg/L from approximately 100 mg/L of total soluble expressed IgA1 protease. We have developed a novel IgA1 protease activity assay using an Experion automated electrophoresis system. The proteolytic activity of the IgA1 protease was measured as the decrease in IgA1 concentration per minute (ng/μL/min/ng of IgA1 protease).

Using the method we developed, the average activities of purified IgA1 protease from E. coli C41 (DE3) and IgA1 protease from H. influenzae (from Jiazhou Qiu and Andrew G. Plaut of Tufts Medical Center) were approximately 46 and 27 ng/μL/min per ng of IgA1 protease, respectively. The IgA1 protease produced from H. influenzae showed lower activity in this experiment probably due to impurity or degradation of the H. influenzae IgA1 protease sample (Figure 6, the extra low molecular weight band in the first line: HI IgA1 protease).

4. Discussion

The serine-type IgA1 protease precursor is composed of four domains: signal peptide, protease domain, α-protein domain, and β-core domain. The previous attempts to
Table 2: Screening the expression of soluble IgA1 proteases by ELISA.

| Construct | First round screening | Second round screening | Third round screening |
|-----------|-----------------------|------------------------|-----------------------|
|           |                       | Expression level (OD450) |                       |
| Control   |                       |                        |                       |
| Negative control: BL21(DE3) supernatant | 0.10 |                        |                       |
| Positive control: purified IgA1 protease | 0.21 |                        |                       |
| Negative control: BL21(DE3) supernatant | 0.08 |                        |                       |
| C41(DE3)  | 1.13                  | 0.4 mM IPTG, 12°C      | 0.72                  |
|           |                       | 15°C, 0.2 mM IPTG      | 0.57                  |
|           |                       | 20°C, 0.2 mM IPTG      | 0.72                  |
|           |                       | 0.4 mM IPTG, 20°C      | 1.10                  |
|           |                       | 15°C, 0.4 mM IPTG      | 0.54                  |
|           |                       | 20°C, 0.4 mM IPTG      | 0.87                  |
| BL21(DE3) | 0.93                  | 1 mM IPTG, 12°C        | 0.66                  |
|           |                       | 20°C, 0.4 mM IPTG      | 1.17                  |
| Origami B(DE3) | 0.98 | 1 mM IPTG, 12°C        | 0.35                  |
|           |                       | 20°C, 0.4 mM IPTG      | 0.54                  |
|           |                       | 1 mM IPTG, 20°C        | 0.66                  |
| BL21(DE3)pGro7 | 1.01 | 1 mM IPTG, 12°C        | 0.46                  |
|           |                       | 20°C, 0.4 mM IPTG      | 0.67                  |
| Tuner (DE3) | 0.92 | 1 mM IPTG, 20°C        | 0.57                  |
|           |                       | 0.4 mM IPTG, 12°C      | 0.48                  |
|           |                       | 0.4 mM IPTG, 20°C      | 0.73                  |
| ArcticExpress (DE3) | 1.00 | 1 mM IPTG, 12°C        | 0.61                  |
|           |                       | 0.4 mM IPTG, 20°C      | 0.47                  |
| BL21(DE3)pGro7 | 1.01 | 1 mM IPTG, 12°C        | 0.54                  |
| KRX       | 0.56                  | 0.4 mM IPTG, 20°C      | 0.70                  |
| Origami B(DE3)pLysS | 0.75 | 1 mM IPTG, 20°C        | 0.89                  |
| C43 (DE3) | 0.14                  | 0.4 mM IPTG, 12°C      | 0.68                  |

Note: IPTG concentrations and temperatures indicate the conditions under which the expression was measured.
| Expression level (OD450) | First round screening | Second round screening | Third round screening |
|--------------------------|-----------------------|------------------------|----------------------|
| **pET-S-IGAN**           |                       |                        |                      |
| BL21(DE3)                | 0.90                  |                        |                      |
| C41(DE3)                 | 0.83                  |                        |                      |
| C43(DE3)                 | 0.20                  |                        |                      |
| Origami B(DE3)           | 0.82                  |                        |                      |
| KRX                     | 0.73                  |                        |                      |
| ArcticExpress(DE3)       | 0.85                  |                        |                      |
| BL21(DE3)pGro7           | 0.86                  |                        |                      |
| Tuner (DE3)              | 0.82                  |                        |                      |
| **pCold-S-IGAN**         |                       |                        |                      |
| BL21(DE3)                | 0.76                  |                        |                      |
| C41(DE3)                 | 0.70                  |                        |                      |
| C43(DE3)                 | 0.79                  |                        |                      |
| Origami B(DE3)           | 0.70                  |                        |                      |
| BL21(DE3)pGro7           | 0.44                  |                        |                      |
| **pCold-IGAN**           |                       |                        |                      |
| BL21(DE3)                | 0.56                  |                        |                      |
| C41(DE3)                 | 0.68                  |                        |                      |
| C43(DE3)                 | 0.15                  |                        |                      |
| Origami B(DE3)           | 0.24                  |                        |                      |
| BL21(DE3)pGro7           | 0.28                  |                        |                      |

**Table 2**: Continued.

**Figure 4**: Expressed soluble IgA1 proteases were active. IgA1 was incubated with cell lysates or soluble supernatant at 37°C overnight. SDS-PAGE (reduced condition) and Western blotting with anti-IgA Ab were employed to detect the cleavage. IgA1 was cleaved by soluble supernatant (or cell lysate) induced at 12°C with 0.4 mM IPTG (except some were induced at 37°C with 1 mM IPTG for 3 hours).
produce natural IgA proteases from *H. influenzae*, *N. gonorrhoeae*, and *N. meningitides* resulted in a very low titer of total IgA proteases. Moreover, the yield of purified IgA1 proteases directly from the cell culture media was low (0.03 and <0.007 mg/L) [23, 24]. It has been reported that IgA1 proteases are capable of being expressed in *E. coli* as inclusion bodies or being secreted to the media with reduced activity, or no activity, or in low yield of recovered recombinant IgA1 proteases [25–27]. Unlike previous attempts to express recombinant, full-length IgA1 protease precursor in *E. coli*, our approach was to screen four IgA1 protease constructs (pET-S-IGAN, pET-IGAN, pCold-S-IGAN, and pCold-IGAN) encoding polypeptides comprising the protease domain only (and lacking the α protein and β-core domains) in various *E. coli* strains. Various conditions for the expression of soluble and active IgA1 proteases were used. Our results demonstrated that all four IgA1 protease constructs were able to produce soluble and active IgA1 proteases in several *E. coli* strains when induced at low temperature and low concentration of IPTG. ELISA as well as activity assay showed that soluble, active IgA1 proteases were expressed in several *E. coli* strains over a range of culture temperatures and IPTG culture concentration. C41 (DE3) cells transformed with the pET-IGAN construct had the highest titer (approximately 100 mg/L) when induced with 0.4 mM IPTG at 20°C. The titer is much higher than the previous report in which it has up to around 2 mg/L [23]. It is possible that the present methods can produce significant amounts of soluble and active IgA1 proteases because the host cells (e.g., *E. coli*) express only the protease domain and not the full-length precursor protein. Thus, the expressed polypeptide does not need to be cleaved into the mature protease, unlike previous recombinant expressions in *H. influenzae* and other bacteria. Because the IgA1 protease was expressed as a C-terminal his-tagged form, it was easily purified with much higher yield (20–40 mg/L), which is more than 1000-folds than the highest yield from previous report (0.03 mg/L) [23].

We report, for the first time, the expression of only the IgA1 protease proteolytic domain without the α protein domain or the β-core domain, for recombinant production of soluble and active IgA1 proteases. The protease domain alone was confirmed to have full protease activity. Under optimized conditions, it was also expressed as soluble and active form in *E. coli*. This method uses *E. coli* instead of pathogenic bacteria such as *H. influenzae*, *N. gonorrhoeae*, and *N. meningitides*. In addition, the significantly increased yield of the IgA1 proteases using the current method allows for production of the IgA1 proteases in amounts useful for administration to treat IgA nephropathy and other IgA deposition diseases.

**Acknowledgments**

The authors thank Jiazhou Qiu and Andrew G. Plaut of Tufts Medical Center for supplying plasmid pFG26 containing *H. influenzae* IgA1 protease gene and purified IgA1 protease from *H. influenzae*. The authors are grateful to BioMarin colleagues Paul Fitzpatrick for technical help, Melita Dvorak-Ewell for helpfully reviewing the manuscript, and Tim Taylor for conducting the fermentation.
References

[1] A. G. Plaut, “The IgA1 proteases of pathogenic bacteria,” Annual Review of Microbiology, vol. 37, pp. 603–622, 1983.

[2] M. Kilian, J. Reinholdt, H. Lomholt, K. Poulsen, and E. V. G. Frandsen, “Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence,” APMIS, vol. 104, no. 5, pp. 321–338, 1996.

[3] J. Qiu, G. P. Bracke, and A. G. Plaut, “Analysis of the specificity of bacterial immunoglobulin A (IgA) proteases by a comparative study of ape serum IgAs as substrates,” Infection and Immunity, vol. 64, no. 3, pp. 933–937, 1996.

[4] K. Kosowska, J. Reinholdt, L. K. Rasmussen et al., “The Clostridium ramosum IgA proteinase represents a novel type of metalloendopeptidase,” The Journal of Biological Chemistry, vol. 277, no. 14, pp. 11987–11994, 2002.

[5] B. W. Senior and J. M. Woof, “The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases,” The Journal of Immunology, vol. 174, no. 12, pp. 7792–7799, 2005.

[6] M. R. Batten, B. W. Senior, M. Kilian, and J. M. Woof, “Amino acid sequence requirements in the hinge of human immunoglobulin A1 (IgA1) for cleavage by streptococcal IgA1 proteases,” Infection and Immunity, vol. 71, no. 3, pp. 1462–1469, 2003.

[7] B. W. Senior and J. M. Woof, “Effect of mutations in the human immunoglobulin A1 (IgA1) hinge on its susceptibility to cleavage by diverse bacterial IgA1 proteases,” Infection and Immunity, vol. 73, no. 3, pp. 1515–1522, 2005.

[8] K. R. Chintalacharuvu, P. D. Chuang, A. Dragoman et al., “Cleavage of the human immunoglobulin A1 (IgA1) hinge region by IgA1 proteases requires structures in the Fc region of IgA,” Infection and Immunity, vol. 71, no. 5, pp. 2563–2570, 2003.

[9] B. W. Senior and J. M. Woof, “Sites in the CH3 domain of human IgA1 that influence sensitivity to bacterial IgA1 proteases,” The Journal of Immunology, vol. 177, no. 6, pp. 3913–3919, 2006.

[10] J. Pohliner, R. Halter, K. Beyreuther, and T. F. Meyer, “Gene structure and extracellular secretion of Neisseria gonorrhoeae IgA protease,” Nature, vol. 325, no. 6103, pp. 458–462, 1987.

[11] W. W. Bachovchin, A. G. Plaut, G. R. Flentke, M. Lynch, and C. A. Kettner, “Inhibition of IgA1 proteinases of Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids,” The Journal of Biological Chemistry, vol. 265, no. 7, pp. 3738–3743, 1990.

[12] M. H. Bender and J. N. Weiser, “The atypical aminoterminal LPNTG-containing domain of the pneumococcal human IgA1-specific protease is required for proper enzyme localization and function,” Molecular Microbiology, vol. 61, no. 2, pp. 526–543, 2006.

[13] A. Arzese and G. A. Botta, “Comparative studies of the IgA1 protease genes from Haemophilus influenzae, Neisseria gonorrhoeae, and Prevotella melaninogena,” Clinical Infectious Diseases, vol. 20, no. 2, pp. S169–S171, 1995.

[14] A. G. Plaut, R. J. Genco, and T. B. Tomasi Jr., “Production of an Fc fragment from human immunoglobulin A by an IgA-specific bacterial protease,” Advances in Experimental Medicine and Biology, vol. 45, no. 0, pp. 245–249, 1994.

[15] E. V. G. Frandsen, M. Kjeldsen, and M. Kilian, “Inhibition of prevotella and Capnocytophaga immunoglobulin A1 proteases by human serum,” Clinical and Diagnostic Laboratory Immunology, vol. 4, no. 4, pp. 458–464, 1997.

[16] S. N. Emancipator, J. Mestecky, and M. E. Lamm, “IgA nephropathy and related diseases,” in Mucosal Immunology, J. Mestecky, J. Bienenson, M. E. Lamm, L Mayer, J. R. McGhee, and W. Strober, Eds., pp. 1580–1600, Elsevier, San Diego, Calif, USA, 2005.

[17] L. Gesualdo, S. Ricanati, M. O. Hassan, S. N. Emancipator, and M. E. Lamm, “Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy,” The Journal of Clinical Investigation, vol. 86, no. 3, pp. 715–722, 1990.

[18] M. Nakazawa, S. N. Emancipator, and M. E. Lamm, “Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis,” Journal of Experimental Medicine, vol. 164, no. 6, pp. 1973–1987, 1986.

[19] M. E. Lamm, S. N. Emancipator, J. K. Robinson et al., “Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy,” American Journal of Pathology, vol. 172, no. 1, pp. 31–36, 2008.

[20] V. Romanello, M. Maracci, F. D. Molin et al., “Cloning, expression, purification, and characterization of Streptococcus pneumoniae IgA1 protease,” Protein Expression and Purification, vol. 45, no. 1, pp. 142–149, 2006.

[21] A. Zhang, X. Mu, B. Chen et al., “Identification and characterization of IgA1 protease from Streptococcus suis,” Veterinary Microbiology, vol. 140, no. 1-2, pp. 171–175, 2009.

[22] E. Veiga, E. Sugawara, H. Nikaido, V. de Lorenzo, and L. A. Fernández, “Export of autotransported proteins proceeds through an oligomeric ring shaped by C-terminal domains,” The EMBO Journal, vol. 21, no. 9, pp. 2122–2131, 2002.

[23] R. Halter, I. Pohliner, and T. F. Meyer, “IgA protease of Neisseria gonorrhoeae: isolation and characterization of the gene and its extracellular product,” The EMBO Journal, vol. 3, no. 7, pp. 1595–1601, 1984.

[24] D. A. Simpson, R. P. Hausinger, and M. H. Mulks, “Purification, characterization, and comparison of the immunoglobulin A1 proteases of Neisseria gonorrhoeae,” Journal of Bacteriology, vol. 170, no. 4, pp. 1866–1873, 1988.

[25] V. G. Khomenkov, T. N. Kazeeva, B. I. Shevelev, V. P. Bargrasser, M. I. Skoblov, and A. B. Shevelev, “Cloning and expression of the IGA-specific endopeptidase genes from Neisseria meningitidis,” Molekuliarnaia Genetika, Mikrobiologiia I Virusologii, no. 1, pp. 30–35, 2007.

[26] F. J. Grundy, A. Plaut, and A. Wright, “Haemophilus influenzae immunoglobulin A1 protease genes: cloning by plasmid integration-excision, comparative analyses, and localization of secretion determinants,” Journal of Bacteriology, vol. 169, no. 10, pp. 4442–4450, 1987.

[27] S. Vitovski and J. R. Sayers, “Relaxed cleavage specificity of an immunoglobulin A1 protease from Neisseria meningitidis,” Infection and Immunity, vol. 75, no. 6, pp. 2875–2885, 2007.